ReviewCold Spring Harbor perspectives in medicine2012
HIV-1 antiretroviral drug therapy.
Review in Cold Spring Harbor perspectives in medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04165200 (Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV), which is not on this map. Cited by 409 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
Who cites it
409 citing papers in PubMed, 5 syntheses or guidelines pooled it, 843 citations in OpenAlex.
- Adjuvant roles of interleukin-7 in enhancing T cell recovery during antiretroviral therapy for individuals with HIV: a systematic review and meta-analysis.Annals of medicine · 2025Pooled it
- Recent Advances in Nitrogen-Containing Heterocyclic Scaffolds as Antiviral Agents.Medicinal chemistry (Shariqah (United Arab Emirates)) · 2024Pooled it
- Current ARTs, Virologic Failure, and Implications for AIDS Management: A Systematic Review.Viruses · 2023Pooled it
- Pooled it
- Mortality in congenital hemophilia A - a systematic literature review.Journal of thrombosis and haemostasis : JTH · 2021Pooled it
- A Randomized Phase 1 Study Evaluating Pharmacokinetics, Safety, and Tolerability of a High-Concentration, Long-Acting Cabotegravir Formulation in Adults Without HIV.Clinical pharmacology in drug development · 2025Trial
- Long-acting cabotegravir pharmacokinetics with and without oral lead-in for HIV PrEP.Antimicrobial agents and chemotherapy · 2024Trial
- Phase IIa Proof-of-Concept Evaluation of the Antiviral Efficacy, Safety, Tolerability, and Pharmacokinetics of the Next-Generation Maturation Inhibitor GSK3640254.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022Trial
- Relative Bioavailability and Food Effect of GSK3640254 Tablet and Capsule Formulations in Healthy Participants.Clinical pharmacology in drug development · 2022Trial
- HIV cure: from early therapies to cutting-edge strategies.Journal of neurovirology · 2026Review
- Article
- Capsid stabilization reprograms the nuclear fate of the HIV genome.Science advances · 2026Article
- Single-cell analysis of HIV expression and integration sites reveals robust viral expression across diverse chromatin environments.Microbiology spectrum · 2026Article
- Cotranslational Folding and "Constrained Monomers" in the Maturation of HIV-1 Protease.Journal of molecular biology · 2026Article
- HIV Tat-activated microglial extracellular vesicles induce neuronal iron dysregulation and synaptodendritic injury.Cell communication and signaling : CCS · 2026Article
- Rhodococcus folensis sp. nov., an orange-red-pigmented bacterium from mining soil.Scientific reports · 2026Article
- Prevalence, associated factors and geospatial patterns of HIV drug resistance in South Africa among the virally unsuppressed adults: updated results from the 2017 national HIV household survey.BMC public health · 2026Article
- Mechanistic insights into lenacapavir-induced off-pathway HIV-1 capsid assembly.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Protein-Linker Co-engineering for Broad-Spectrum Antiviral Development against Enveloped Viruses.ACS materials letters · 2026Article
- Biological Activity of Stilbenoids Against Fungal, Parasitic, and Viral Pathogens.Molecules (Basel, Switzerland) · 2026Review
349 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
The most significant advance in the medical management of HIV-1 infection has been the treatment of patients with antiviral drugs, which can suppress HIV-1 replication to undetectable levels. The discovery of HIV-1 as the causative agent of AIDS together with an ever-increasing understanding of the virus replication cycle have been instrumental in this effort by providing researchers with the knowledge and tools required to prosecute drug discovery efforts focused on targeted inhibition with specific pharmacological agents. To date, an arsenal of 24 Food and Drug Administration (FDA)-approved drugs are available for treatment of HIV-1 infections. These drugs are distributed into six distinct classes based on their molecular mechanism and resistance profiles: (1) nucleoside-analog reverse transcriptase inhibitors (NNRTIs), (2) non-nucleoside reverse transcriptase inhibitors (NNRTIs), (3) integrase inhibitors, (4) protease inhibitors (PIs), (5) fusion inhibitors, and (6) coreceptor antagonists. In this article, we will review the basic principles of antiretroviral drug therapy, the mode of drug action, and the factors leading to treatment failure (i.e., drug resistance).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.